Arihant Capital Markets (Manager to the Offer) on behalf of Ipca Laboratories (Acquirer) has informed this Corrigendum to the DPS in respect of the Open Offer to the Equity Shareholders of Krebs Biochemicals and Industries (Target Company) pursuant to and in compliance with Regulation 3(1) and (4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and amendments thereto (SEBI SAST Regulations). This Corrigendum is being issued pursuant to changes / amendments advised by SEBI vide their letter dated October 21, 2015 and should be read in conjunction with the DPS published on February 24, 2015 in publications. The terms used in this Corrigendum to the DPS have the same meaning assigned to them in the DPS issued earlier, unless otherwise specified.
The above information is a part of company’s filings submitted to BSE.
